

Attorney Docket No. 4172-15-1  
Express Mail No. EV 586167825 US

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANT:	BAR-OR ET AL.	}	EXAMINER: SHAHNAN SHAH, K.S.
SERIAL NO.:	09/820,416		
FILED:	MARCH 29, 2001		
TITLE:	MARKER USEFUL FOR DETECTION AND MEASUREMENT OF FREE RADICAL DAMAGE AND METHOD		
			ART UNIT: 1645
			CONFIRMATION NO.: 5597

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

**INFORMATION DISCLOSURE STATEMENT**

Applicant calls the Examiner's attention to the patents and publications listed on the attached Form PTO-1449, copies of required documents enclosed, which may be material to examination of the above identified application.

TIME OF TRANSMITTAL

This Information Disclosure Statement is being filed under 37 CFR § 1.97(b). This Statement is filed within at least one of the following time periods:

- (a) within three months of the filing date of a national application (other than a CPA under 37 CFR § 1.53(d));
- (b) within three months of the date of entry of the national stage as set forth in 37 CFR § 1.491 in an international application;
- (c) before the mailing of a first Office Action of the merits; or
- (d) before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR § 1.114.

No fee is believed to be due in this instance. However, the undersigned hereby authorizes the charging of any fees created by the filing of this document to Deposit Account No. 19-5117.

The filing of this Information Disclosure Statement shall not be construed as an admission against interest in any manner. This listed patents and publications are believed of

interest herein and consideration and citation of as interest by Examiner is respectfully requested.

Enclosed is a copy of a Petition for Withdrawal from Issue under 37 C.F.R. §1.313(c)(2), which was submitted via facsimile on even date herewith. If the Examiner has any questions or comments, she is invited to phone the undersigned.

Respectfully submitted,


Date: March 31, 2005

Margaret M. Wall  
Margaret M. Wall, #33,462  
Swanson & Bratschun, L.L.C.  
1745 Shea Center Drive, Suite 330  
Highlands Ranch, Colorado 80129  
Telephone: (303) 268-0066  
Facsimile: (303) 268-0065

cc: H. Huff w/out refs

A. Torrance w/out refs

S:\CLIENTFOLDERS\ISCHEMIA\4172-15\15-1\IDS.DOC



FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  List of Information Cited by Applicant  Page 1 of 1	ATTY. DOCKET NO.	SERIAL NO.
	APPLICANT	
	FILING DATE	GROUP

U.S. PATENT DOCUMENTS							
EXAM. INITIAL		DOCUMENT NUMBER	DATE	NAME	CLS	SUB- CLS	FILE DATE
	AA	2004-0175754	9/9/04	BAR-OR ET AL.			
	AB	2004-0209379	10/21/04	BAR-OR ET AL.			
	AC	6,767,708	7/27/04	WILLIAMS ET AL.			
	AD	2003-017506	1/23/03	BAR-OR ET AL.			
	AE	5,326,707	7/5/94	FRANKE ET AL.			
	AF	5,876,969	3/2/99	FLEER ET AL.			
	AG	6,235,489	5/22/01	JACKOWSKI			
	AH	6,274,305	8/14/01	SONNENSCHN ET AL.			
	AI						

FOREIGN PATENT DOCUMENTS							
EXAM. INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLS	SUB CLS	TRANS ?
	AJ	WO 04/030522	4/15/04	PCT			
	AK						
	AL						
	AM						
	AN						
	AO						

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
	AP	Apple et al. (2002) Clin. Chem. 48:10
	AQ	Bar-Or et al. (1999) "Reduction in the Cobalt Binding Capacity of Human Albumin with Myocardial Ischemia", Amer. Coll. Emerg. Physicians, Las Vegas, Sept 1999
	AR	Belch et al. (1989) Free Radic. Biol. Med. 6(4):375-378
	AS	Berenshtein et al. (1997) J Mol Cell Cardiol. 29(11):3025-34
	AT	Bradshaw et al. (1968) J. Biol. Chem. 243:3817-25
	AU	Bradshaw et al. (1969) J. Biol. Chem. 244:5582-89
	AV	Christenson et al. (2001) Clin. Chem. 47:464-70
	AW	Dorland's Illustrated Medical Dict. (2002) pp. 911, 1275
	AX	Cin et al. (1996) Int. J. Cardiol. 53:237-244
	AY	Gryzunov et al. (2003) Arch. Biochem. Biophys. 413(1):53-56
	AAA	Morris et al. (2001) Eur. Heart J. Abs. Supp 22:608
	AAB	Wu et al. (2001) Cardiovascular Toxicol.1:147-151
	AAC	Wu, A. (2000) "The Albumin Cobalt Binding Test as a Marker of Cardiac Ischemia" at the Third Annual Joint Summit on Markers in Cardiology
EXAMINER		
DATE CONSIDERED		
*EXAMINER: Initial if refrence considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		